Scarica l'app Stockscreener
3.09
1.48%
0.045
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.045
Aprire:
$3.04
Volume 24 ore:
12,112
Relative Volume:
0.16
Capitalizzazione di mercato:
$97.99M
Reddito:
-
Utile/perdita netta:
$-10.74M
Rapporto P/E:
-8.8286
EPS:
-0.35
Flusso di cassa netto:
$-6.53M
1 W Prestazione:
-1.28%
1M Prestazione:
+0.98%
6M Prestazione:
+13.19%
1 anno Prestazione:
+6.55%
Intervallo 1D:
$3.0201
$3.13
Intervallo di 1 settimana:
$3.02
$3.2595
Portata 52W:
$2.145
$5.13
Anixa Biosciences Inc Stock (ANIX) Company Profile
Nome
Anixa Biosciences Inc
Settore
Industria
Telefono
408-708-9808
Indirizzo
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Confronta ANIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ANIX | 3.0964 | 97.99M | 0 | -10.74M | -6.53M | -0.35 |
| VRTX | 449.33 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.35 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.58 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.96 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-23 | Iniziato | Chardan Capital Markets | Buy |
| 2021-04-12 | Iniziato | H.C. Wainwright | Buy |
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
Anixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Anixa Hikes on Tests - Baystreet.ca
Anixa Biosciences Advances Ovarian Cancer CAR-T Trial with 10x Dose Increase | ANIX Stock News - StockTitan
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in October - Defense World
Anixa Biosciences, Inc. (NASDAQ:ANIX) Sees Large Decrease in Short Interest - MarketBeat
Anixa Biosciences Inc. (ANIX) Quarterly 10-Q Report - Quartz
Anixa reports progress in breast cancer vaccine trial - Investing.com
Anixa reports progress in breast cancer vaccine trial By Investing.com - Investing.com Canada
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
Anixa Biosciences Reports Promising Phase 1 Vaccine Results - TipRanks
Anixa Biosciences to Present Phase 1 Breast Cancer Vaccine Trial Data at SITC Meeting | ANIX Stock News - StockTitan
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
ANIXA BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 - StockTitan
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
US Penny Stocks To Consider In October 2024 - Simply Wall St
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial - Yahoo Finance
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Drops By 8.9% - MarketBeat
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development - BioSpace
Anixa Biosciences Seeks Protocol Change to Enable Repeat Dosing in Trial for Ovarian Cancer CER-T - CGTLive™
Anixa seeks approval for repeat CAR-T doses in ovarian cancer trial By Investing.com - Investing.com South Africa
Anixa seeks approval for repeat CAR-T doses in ovarian cancer trial - Investing.com
California Biotech's Target Price 200% Higher Than Current - Streetwise Reports
ANIXAnixa Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial - StockTitan
Anixa announces plans to launch Phase II breast cancer vaccine trial - Clinical Trials Arena
Anixa Shares Rise on Plans for Phase 2 Study of Breast Cancer Vaccine - MarketWatch
Anixa Biosciences sets Phase 2 trial for breast cancer vaccine - Investing.com
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine - PR Newswire
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
FY2024 EPS Estimates for Anixa Biosciences, Inc. (NASDAQ:ANIX) Lifted by Analyst - MarketBeat
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference - PR Newswire
HC Wainwright Reaffirms Buy Rating for Anixa Biosciences (NASDAQ:ANIX) - MarketBeat
Why researchers hope a new vaccine will help in the fight against breast cancer - FOX 13 News Utah
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate - Simply Wall St
Anixa Biosciences (NASDAQ:ANIX) Announces Earnings Results - MarketBeat
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium - StockTitan
Nations Financial Group Inc. IA ADV Has $50,000 Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Anixa Biosciences to Present at Biotech Showcase 2024 - GuruFocus.com
Anixa Biosciences (FRA:CY71) Earnings per Share (Diluted) : €-0.34 (TTM As of Apr. 2024) - GuruFocus.com
ANIX (Anixa Biosciences) GF Value Rank : 0 (As of Aug. 16, 2024) - GuruFocus.com
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Grows By 33.0% - MarketBeat
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Update - Defense World
Virtu Financial LLC Has $50,000 Stake in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Upgraded by EF Hutton Acquisition Co. I - MarketBeat
Anixa Biosciences (NASDAQ:ANIX) Upgraded to “Strong-Buy” at EF Hutton Acquisition Co. I - Defense World
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Purchases 21,646 Shares of Stock - Defense World
Anixa Biosciences Inc Azioni (ANIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anixa Biosciences Inc Azioni (ANIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jul 30 '24 |
Buy |
3.06 |
21,646 |
66,237 |
890,754 |
| Titterton Lewis H jr | Director |
Jul 31 '24 |
Buy |
3.23 |
5,580 |
18,023 |
896,334 |
| Titterton Lewis H jr | Director |
Jul 26 '24 |
Buy |
3.03 |
7,700 |
23,331 |
869,108 |
| Titterton Lewis H jr | Director |
Jul 25 '24 |
Buy |
2.81 |
796 |
2,237 |
861,408 |
| Baskies Arnold M | Director |
Jul 26 '24 |
Buy |
3.09 |
5,000 |
15,450 |
115,000 |
| Titterton Lewis H jr | Director |
Jun 14 '24 |
Buy |
2.68 |
4,000 |
10,720 |
860,612 |
| Titterton Lewis H jr | Director |
Jun 13 '24 |
Buy |
2.70 |
405 |
1,094 |
856,612 |
| Titterton Lewis H jr | Director |
Jun 11 '24 |
Buy |
2.66 |
7,102 |
18,891 |
856,207 |
| Titterton Lewis H jr | Director |
Jun 10 '24 |
Buy |
2.60 |
330 |
858 |
849,105 |
| Titterton Lewis H jr | Director |
Jun 07 '24 |
Buy |
2.52 |
10,738 |
27,060 |
848,775 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):